The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 11, 2008, Pages 1288-1297

  Delgado, Julio ^a   Pillai, Srinivas ^b   Benjamin, Reuben ^c   Caballero, Dolores ^d   Martino, Rodrigo ^a   Nathwani, Amit ^c   Lovell, Richard ^b   Thomson, Kirsty ^c   Perez Simon, Jose A ^d   Sureda, Anna ^a   Kottaridis, Panagiotis ^c   Vazquez, Lourdes ^d   Peggs, Karl ^c   Sierra, Jorge ^a   Milligan, Donald ^b   Mackinnon, Stephen ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Alemtuzumab; Allogeneic hematopoietic cell transplantation; Chronic lymphocytic leukemia; T cell depletion

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DONOR; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IN VIVO STUDY; LEUKEMIA RELAPSE; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OVERALL SURVIVAL; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; T CELL DEPLETION; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION; VOLUNTEER;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; DONOR SELECTION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 53749096361     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.09.001     Document Type: Article

References (48)

1. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 (2005) 804-815
2. Kay N.E., O'Brien S.M., Pettitt A.R., and Stilgenbauer S. The role of prognostic factors in assessing "high-risk" subgroups of patients with chronic lymphocytic leukemia. Leukemia 21 (2007) 1885-1891
3. Shanafelt T.D., Byrd J.C., Call T.G., Zent C.S., and Kay N.E. Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 145 (2006) 435-447
4. Dores G.M., Anderson W.F., Curtis R.E., et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139 (2007) 809-819
5. Mauro F.R., Foa R., Giannarelli D., et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94 (1999) 448-454
6. Khouri I.F., Keating M.J., Saliba R.M., and Champlin R.E. Long-term follow-up of patients treated with CLL with allogeneic hematopoietic transplantation. Cytotherapy 4 (2002) 217-221
7. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia: European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 124 (1996) 311-315
8. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111 (2000) 18-29
9. Gine E., Moreno C., Esteve J., and Montserrat E. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Pract Res Clin Haematol 20 (2007) 529-543
10. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21 (2007) 12-17
11. Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20 (2006) 1661-1672
12. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11 (2005) 7757-7763
13. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
14. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107 (2006) 1724-1730
15. H gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107 (2006) 1023-1033
16. Przepiorka D., Weisdorf D., Martin P., et al. Consensus conference of acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
17. Atkinson K., Horowitz M.M., Gale R.P., et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease: Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4 (1989) 247-254
18. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
19. Lunn M., and McNeil D. Applying Cox regression to competing risks. Biometrics 51 (1995) 524-532
20. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
21. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4070-4078
22. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
23. Coiffier B., Lepretre S., Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111 (2008) 1094-1100
24. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
25. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (2006) 5343-5349
26. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32 (2004) 28-35
27. Moreno C., Villamor N., Colomer D., et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3433-3438
28. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
29. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12 (2006) 1056-1064
30. Sorror M.L., Storer B.E., Maloney D.G., et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111 (2008) 446-452
31. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
32. Frassoni F., Labopin M., Powles R., et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet 355 (2000) 1393-1398
33. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
34. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26 (2008) 577-584
35. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
36. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106 (2005) 2969-2976
37. Dreger P., Ritgen M., Böttcher S., Schmitz N., and Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?. Leukemia 19 (2005) 1135-1138
38. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100 (2002) 3108-3114
39. Schetelig J., Thiede C., Bornhäuser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 (2003) 2747-2753
40. Hoogendoorn M., Jedema I., Barge R.M.Y., et al. Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning. Leukemia 21 (2007) 2569-2574
41. Khouri I.F., Saliba R.M., Admirand J., et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137 (2007) 355-363
42. Hensel M., Kornacker M., Yammeni S., Egerer G., and Ho A.D. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122 (2003) 600-606
43. Oscier D., Fegan C., Hillmen P., et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 125 (2004) 294-317
44. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94 (1999) 2208-2216
45. Orsini E., Guarini A., Chiaretti S., Mauro F.R., and Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 63 (2003) 4497-4506
46. Pavletic S.Z., Khouri I.F., Haagenson M., et al. Unrelated donor transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol 23 (2005) 5788-5794
47. Keating M.J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43 (2002) 1755-1762
48. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561